Biomarkers in Blood Samples From Patients With Refractory Non-Small Cell Lung Cancer Previously Treated With Sorafenib Tosylate
|ClinicalTrials.gov Identifier: NCT01124669|
Recruitment Status : Completed
First Posted : May 17, 2010
Last Update Posted : May 17, 2017
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research study is studying biomarkers in blood samples from patients with refractory non-small cell lung cancer previously treated with sorafenib tosylate.
|Condition or disease||Intervention/treatment|
|Lung Cancer||Genetic: DNA analysis Genetic: mutation analysis Other: laboratory biomarker analysis|
- To determine the mutation rates of BRAF, KRAS, and EGFR in patients with non-small cell lung cancer treated with sorafenib tosylate on protocol ECOG-2501.
- To determine the association between BRAF, KRAS, or EGFR mutation status and clinical benefits in patients treated with this regimen.
OUTLINE: This is a multicenter study.
DNA is isolated from archived plasma samples and analyzed for BRAF, KRAS, and EGFR mutations.
|Study Type :||Observational|
|Actual Enrollment :||80 participants|
|Official Title:||BRAF, KRAS and EGFR Mutation Detection in Non-Small Cell Lung Cancer Patients Treated With Sorafenib Monotherapy|
|Actual Study Start Date :||June 13, 2010|
|Primary Completion Date :||July 13, 2010|
|Study Completion Date :||July 13, 2010|
- Mutation rate of sorafenib tosylate-target gene BRAF, and its upstream proteins KRAS and EGFR [ Time Frame: 1 mont ]
- Association between BRAF, KRAS, and EGFR mutation status and clinical benefits (stable disease or partial response) [ Time Frame: 1 month ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01124669
|Principal Investigator:||Christine Chung, MD||Vanderbilt-Ingram Cancer Center|